New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.2%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
168.69
2.16
+1.30%
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) SEC filings, changes and red flags
Red flags
-
Officer departure
Gilead Sciences, Inc. reported the departure of an officer or director
Filings
| Form | Period | Filed | What it reports | Flags |
|---|---|---|---|---|
| 10-Q | Sep 30, 2026 |
P1I2: 11 added · 7 removed · 35 modified P2I1A: 1 removed · 29 modified |
||
| 8-K | Oct 29, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-Q | Jun 30, 2026 |
P1I2: 33 added · 8 removed · 31 modified P2I1A: 2 added · 1 removed · 28 modified |
||
| 8-K | Aug 4, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | May 14, 2026 | 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 10-Q | Mar 31, 2026 |
P1I2: 19 added · 64 removed · 28 modified P2I1A: 1 added · 3 removed · 39 modified |
||
| 8-K | May 7, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Apr 30, 2026 | 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits | ||
| 8-K | Apr 28, 2026 | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 10-K | Dec 31, 2025 |
1: 4 added · 9 removed · 34 modified 1A: 11 added · 7 removed · 43 modified 7: 39 added · 41 removed · 48 modified |
||
| 8-K | Feb 22, 2026 | 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | ||
| 8-K | Feb 10, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Nov 15, 2025 | 5.02 Departure or appointment of directors or officers | Officer departure | |
| 10-Q | Sep 30, 2025 |
P1I2: 40 added · 12 removed · 35 modified P2I1A: 4 added · 5 removed · 30 modified |
||
| 8-K | Oct 30, 2025 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Oct 6, 2025 | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | ||
| 10-Q | Jun 30, 2025 |
P1I2: 30 added · 19 removed · 31 modified P2I1A: 3 added · 1 removed · 39 modified |
||
| 8-K | Aug 7, 2025 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-Q | Mar 31, 2025 | |||
| 8-K | Apr 24, 2025 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-K | Dec 31, 2024 |
1: no comparison — no earlier filing on file 1A: no comparison — no earlier filing on file 7: no comparison — no earlier filing on file |
||
| 8-K | Feb 11, 2025 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-Q | Sep 30, 2024 | |||
| 8-K | Nov 6, 2024 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-Q | Jun 30, 2024 | |||
| 8-K | Aug 8, 2024 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Apr 25, 2024 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Feb 6, 2024 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits |